Key Details
Price
$667.00Annual ROE
16.26%Beta
0.74Events Calendar
Next earnings date:
Feb 04, 2025Recent quarterly earnings:
Oct 31, 2024Recent annual earnings:
Feb 02, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
On February 3, 2025, Bronstein, Gewirtz & Grossman, LLC, a well-known law firm, announced that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. and some of its executives. The lawsuit aims to seek compensation for investors who bought or acquired Regeneron securities from November 2, 2023, to October 30, 2024. This action is based on alleged breaches of federal securities laws during that time.
NEW YORK, Feb. 3, 2025 /PRNewswire/ -- The Gross Law Firm has an important message for shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Those who bought shares of REGN during the specified time are invited to reach out to the firm about the chance to be appointed as lead plaintiff.
If you experienced a loss from your investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and are interested in possible recovery options under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=126668&wire=1 or reach out to Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / February 2, 2025 / If you experienced a loss from your investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and are interested in possible recovery under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=126658&wire=1 or reach out to Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / February 2, 2025 / If you experienced a loss from your investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and are interested in possible recovery under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=126654&wire=1 or reach out to Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / February 2, 2025 / WHY: The Rosen Law Firm, a law firm focused on investor rights, is reminding buyers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities from November 2, 2023, to October 30, 2024, about the important lead plaintiff deadline on March 10, 2025. SO WHAT: If you bought Regeneron securities during this time, you might be eligible for compensation without having to pay any fees upfront, thanks to a contingency fee arrangement.
We have put together a list of the 12 Best S&P 500 Stocks to Invest in Based on Analyst Recommendations. In this article, we will examine how Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) compares to other S&P 500 stocks. The year 2024 was significant for the overall market index, which saw an increase of […]
If you experienced a loss from your investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and are interested in possible recovery options under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=126589&wire=1 or reach out to Joseph E. Levi, Esq.
LOS ANGELES, CA / ACCESS Newswire / February 2, 2025 / The Schall Law Firm, a national firm focused on shareholder rights, is reminding investors about a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN). This lawsuit addresses violations of the Securities Exchange Act of 1934. Investors who bought the Company's securities from November 2, 2023, to October 30, 2024, are urged to reach out to the firm before March 10, 2025.
NEW YORK, NY / ACCESS Newswire / February 2, 2025 / If you experienced a loss from your investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and are interested in possible recovery under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=126541&wire=1 or reach out to Joseph E. Levi, Esq.
FAQ
- What is the primary business of Regeneron Pharmaceuticals?
- What is the ticker symbol for Regeneron Pharmaceuticals?
- Does Regeneron Pharmaceuticals pay dividends?
- What sector is Regeneron Pharmaceuticals in?
- What industry is Regeneron Pharmaceuticals in?
- What country is Regeneron Pharmaceuticals based in?
- When did Regeneron Pharmaceuticals go public?
- Is Regeneron Pharmaceuticals in the S&P 500?
- Is Regeneron Pharmaceuticals in the NASDAQ 100?
- Is Regeneron Pharmaceuticals in the Dow Jones?
- When was Regeneron Pharmaceuticals's last earnings report?
- When does Regeneron Pharmaceuticals report earnings?
- Should I buy Regeneron Pharmaceuticals stock now?